Jim Simons
ALLO icon

Jim Simons’s Allogene Therapeutics ALLO Stock Holding History

Jim Simons’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.22M Sell
2,139,328
-47,756
-2% -$95.7K 0.01% 1359
2025
Q4 		$3M Sell
2,187,084
-706,728
-24% -$932K ﹤0.01% 1629
2025
Q3 		$3.59M Buy
2,893,812
+1,223,800
+73% +$1.46M ﹤0.01% 1678
2025
Q2 		$1.89M Buy
1,670,012
+113,312
+7% +$151K ﹤0.01% 2146
2025
Q1 		$2.27M Buy
1,556,700
+1,002,159
+181% +$1.89M ﹤0.01% 1921
2024
Q4 		$1.18M Sell
554,541
-87,468
-14% -$216K ﹤0.01% 2398
2024
Q3 		$1.8M Sell
642,009
-1,105,946
-63% -$2.95M ﹤0.01% 2095
2024
Q2 		$4.07M Buy
1,747,955
+1,351,055
+340% +$3.99M 0.01% 1442
2024
Q1 		$1.77M Sell
396,900
-61,748
-13% -$258K ﹤0.01% 2111
2023
Q4 		$1.47M Buy
458,648
+428,366
+1,415% +$1.21M ﹤0.01% 2153
2023
Q3 		$96K Sell
30,282
-221,618
-88% -$971K ﹤0.01% 3255
2023
Q2 		$1.25M Sell
251,900
-176,800
-41% -$956K ﹤0.01% 2329
2023
Q1 		$2.12M Sell
428,700
-11,400
-3% -$73.1K ﹤0.01% 1990
2022
Q4 		$2.77M Buy
+440,100
New +$4.07M ﹤0.01% 1876
2022
Q2 		– Sell
-974,700
Closed -$8.88M – 4188
2022
Q1 		$8.88M Buy
+974,700
New +$10.2M 0.01% 1195
2021
Q3 		– Sell
-704,400
Closed -$18.4M – 3440
2021
Q2 		$18.4M Buy
+704,400
New +$20.1M 0.02% 801
2020
Q4 		– Sell
-83,900
Closed -$3.16M – 3356
2020
Q3 		$3.16M Buy
83,900
+58,700
+233% +$2.21M ﹤0.01% 1853
2020
Q2 		$1.08M Buy
+25,200
New +$911K ﹤0.01% 2499

Other funds holding ALLO

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jim Simons's ALLO Position: Q1 2026 in Review

Jim Simons reduced its Allogene Therapeutics (ALLO) stake by 2.2% in Q1 2026, selling an estimated $95.7K and leaving 2,139,328 shares worth $5.22M. The position accounts for 0.01% of the portfolio, ranked #1359.

Jim Simons first reported a position in ALLO in Q2 2020 and has held it in 18 quarters since. The position peaked at $18.4M in Q2 2021. 209 funds tracked by Wall St. Rank hold ALLO as of Q1 2026.

  • Jim Simons held 2,139,328 shares of Allogene Therapeutics worth $5.22M as of Q1 2026.
  • Jim Simons sold 47,756 Allogene Therapeutics shares in Q1 2026, an estimated $95.7K.
  • Allogene Therapeutics made up 0.01% of Jim Simons's portfolio in Q1 2026, its #1359 holding.
  • Jim Simons first reported a position in Allogene Therapeutics in Q2 2020 and has held it in 18 quarters since.
  • Jim Simons's Allogene Therapeutics position peaked at $18.4M in Q2 2021.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.